SLC5A2 and metabolic dysfunction-associated steatotic liver disease: Besides direct effects on hepatic inflammation, reactive oxygen species generation and mitochondrial function SGLT2 inhibitor-induced weight reduction might also contribute to beneficial effects on non-alcoholic fatty liver disease (NAFLD) [10, 11].